The In Vivo Antidiabetic Activity of Nigella sativa Is Mediated through Activation of the AMPK Pathway and Increased Muscle Glut4 Content by Benhaddou-Andaloussi, Ali et al.
Hindawi Publishing Corporation
Evidence-Based Complementaryand Alternative Medicine
Volume 2011, Article ID 538671, 9 pages
doi:10.1155/2011/538671
Research Article
TheInVivo AntidiabeticActivityofNigellasativa Is Mediated
throughActivationoftheAMPK PathwayandIncreased Muscle
Glut4Content
Ali Benhaddou-Andaloussi,1,2 LouisMartineau,1,2 Tri Vuong,1,2 Bouchra Meddah,3
Padma Madiraju,1,2 AbdellatifSettaf,3 andPierre S.Haddad1,2
1Department of Pharmacology and Montreal Diabetes Research Center, Universit´ ed eM o n t r ´ eal, Montr´ eal, QC, Canada H3C 3J7
2Institut des Nutraceutiques et des Aliments Fonctionnels, Laval University, Quebec City, QC, Canada G1K7P4
3Research Team in Pharmacokinetics, Laboratory of Pharmacology and Toxicology, Faculty of Medicine and Pharmacy,
Mohammed V University, Rabat-Souissi, Morocco
Correspondence should be addressed to Pierre S. Haddad, pierre.haddad@umontreal.ca
Received 5 July 2010; Revised 26 January 2011; Accepted 15 February 2011
Copyright © 2011 Ali Benhaddou-Andaloussi et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The antidiabetic eﬀect of N. sativa seed ethanol extract (NSE) was assessed in Meriones shawi after development of diabetes.
Meriones shawi were divided randomly into four groups: normal control, diabetic control, diabetic treated with NSE
(2geqplant/kg) or with metformin (300mg/kg) positive control, both administered by daily intragastric gavage for 4 weeks.
Glycaemia and body weight were evaluated weekly. At study’s end, an Oral Glucose Tolerance Test (OGTT) was performed
to estimate insulin sensitivity. Upon sacriﬁce, plasma lipid proﬁle, insulin, leptin, and adiponectin levels were assessed. ACC
phosphorylation and Glut4 protein content were determined in liver and skeletal muscle. NSE animals showed a progressive
normalization of glycaemia, albeit slower than that of metformin controls. Moreover, NSE increased insulinemia and HDL-
cholesterol, compared to diabetic controls. Leptin and adiponectin were unchanged. NSE treatment decreased OGTT and tended
to decrease liver and muscle triglyceride content. NSE stimulated muscle and liver ACC phosphorylation and increased muscle
Glut4. These results conﬁrm NSE’s previously reported hypoglycaemic and hypolipidemic activity. More signiﬁcantly, our data
demonstrate that in vivo treatment with NSE exerts an insulin-sensitizing action by enhancing ACC phosphorylation, a major
component of the insulin-independent AMPK signalingpathway, and by enhancing muscle Glut4 expression.
1.Introduction
Diabetes is a chronic disease that occurs when the pancreas
does not produce enough insulin, and/or when the body
cannot eﬀectively use the insulin it produces. Hypergly-
caemia, or high blood sugar, is a common eﬀect of uncon-
trolled diabetes and over time leads to serious damage to
many ofthebody’ssystems,especially thenerves,kidney,and
blood vessels [1]. The World Health Organization (WHO)
estimates that more than 180 million people worldwide have
diabetes. This number is likely to more than double by
2030 [1]. Therapeutic interventions for patients with type
II diabetes include diet, exercise, oral hypoglycemic agents,
and/or insulin. For centuries or even millennia, medicinal
plants around the world have also been used to treat the
disease; over a thousand plants being reported to combat
diabetes or its major symptoms [2–4]. The hypoglycaemic
action of these plants is exerted by several mechanisms, such
as stimulation of insulin production [5], enhancement of
insulin sensitivity [6], or inhibition of intestinal amylase [4].
N. sativa is a herbaceous plant growing to about 20–
30cm in height, commonly known as black seed because
of the small triangular black seeds it generates. The plant
is also known as Blessed Seed (Arab: Habbat ul Baraka, or
Habbat ul Sauda). It has been consumed for more than 2000
years, is used extensively in the traditional medicine of many
southern Mediterranean and Middle Eastern countries, and
has been shown to produce multisystemic beneﬁcial actions
[7], including hypocholesterolemic [8], antioxidant [9, 10],
and anti-inﬂammatory eﬀects [11].2 Evidence-Based Complementary and Alternative Medicine
The hypoglycaemic and antidiabetic eﬀect of N. sativa
has been reported by numerous in vivo and in vitro scientiﬁc
studies [9, 12–25]. In a recent study, we have demonstrated
that N. sativa seed ethanol extract (NSE) exhibits the
remarkable ability in vitro to concomitantly increase insulin
secretion, induce proliferation of pancreatic β cells, and
stimulate glucose uptake in skeletal muscle and fat cells
[24]. On the other hand, most of the in vivo studies of the
antidiabetic eﬀect of N. sativa were carried out on models
of type I diabetes. We therefore investigated the eﬀects of
NSE on the diabetic Meriones shawi that represents a model
of type II diabetes associated with hyperinsulinemia and
dyslipidemia. We have also attempted to determine some of
the mechanisms of action through which NSE may exert its
antidiabeticeﬀect,notablyadipokines, AMP-kinase (AMPK)
dependent signalling, and Glut4 protein content.
2.MaterialandMethods
2.1.Reagentsand Antibodies. Antibodies against pan-speciﬁc
and phosphorylated acetyl CoA carboxylase (ACC) (Ser
79), as well as Glut4 antibodies were purchased from
Cell Signaling Technology (Danvers, MA, USA). Secondary
HRP-conjugated antibodies were purchased from Jackson
Immunoresearch (Cedarlane Laboratories, Hornby, ON).
Protein assay kit was purchased from Pierce (Brockville,
ON). Rat Insulin-speciﬁc RIA kit, Rat Leptin RIA kit, and
Mouse Adiponectin RIA kit-125T were purchased from
Linco Research Inc (Saint Charles, MO). Sodium pentobar-
bital, triglyceride, and free glycerol reagents as well as D-
glucose were purchased from Sigma-Aldrich (Saint Louis,
MO).
2.2. Plant Material. Seeds of N. sativa were obtained from
an herbalist in Rabat, Morocco in August 2005 and were
authenticated by an experienced botanist (Professor A.
Oulyahya, Institut Scientiﬁque, Rabat, Morocco). A voucher
specimen has been depositedin the herbarium ofthe Institut
Scientiﬁque of Rabat (no. 10359). Seeds were washed, dried,
and then powdered with an electric microniser. Powder was
extracted three times with 80% ethanol and the solvent
was evaporated at 40◦C under reduced pressure. This
procedure resulted in a two-phased extract. The oily and the
solid phases were recombined in proportion to their yield
(typically 70% and 30%, resp.). The extract was conserved
at 4◦C and protected from light and humidity.
2.3. Animals. One hundred Meriones shawi of both sexes
were captured in the semiarid area of Boulmane in the
MiddleAtlasregionofMorocco.Appropriatetrapswereused
for catching the animals. They were then transported to the
FacultyofMedicineandPharmacyofMohamedVUniversity
in Rabat, Morocco. Animals were allowed to adapt to the
laboratory environment, numbered and placed in individual
cages. All animals received a standard laboratory diet, ad
libitum, which represents a hypercaloric food source for
them.Afterthree monthsofsuchdiet,Meriones shawi having
blood glucose greater than 8mmol/L and having developed
insulin resistance (AUC greater than 1500) were considered
diabetic. This selection has enabled us to have a yield of 25%
diabetic animals.
2.4. Experimental Procedure. Twenty-four diabetic and eight
normal Meriones shawi were divided into four groups of 8
animals each as follows: normal control animals, diabetic
control animals, diabetic NSE treated animals, and diabetic
metformin-treated animals. Treatment was given by daily
intragastric gavage at a dose 48mg/kg/day of N. sativa
extract (equivalent to 2g plant/kg/day) and 300mg/kg/day
metformin for four weeks in one milliliter of 0.5% methyl
cellulose suspension. Control animals received equal volume
ofvehicle(1mL).Glycaemiaandbodyweightweremeasured
every week. At the end of the experimental period (4
weeks), the animals were fasted overnight, anaesthetized
with an intraperitoneal injection of sodium pentobarbital
(60mg/kg), and sacriﬁced for obtaining blood and tissues
samples (liver, soleus muscle). The study was conducted
in accordance with the accepted principles outlined in
t h e“ G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r yA n i m a l s ”
prepared by the National AcademyofSciencesand published
by the National Institutes ofHealth and all eﬀortswere made
to minimize animal suﬀering and the number of animals
used. Ethics approval was obtained from Mohammed V
University.
2.5. Oral Glucose Tolerance Test (OGTT). One day before the
beginning and the end of the experiment, an Oral Glucose
Tolerance Test (OGTT) was performed to assess glucose
tolerance. For this purpose, overnight fasted rats were fed
D-glucose (3g/kg body weight) by intragastric gavage, and
then blood was collected after 0, 15, 30, 60, and 120min
intervals from the tail vein. Plasma glucose concentrations
w e r ed e t e r m i n e db yt h eg l u c o s eo x y d a s em e t h o du s i n ga
glucometer (One Touch Ultra, LifeScan Inc, Milpitas, CA).
The areas under the curve (AUC) of changes in the blood
glucose were calculated by using Origin software (Microcal
Inc, Northampton, MA).
2.6. Plasma Lipid Assays. After 4 weeks of the treatment,
Meriones shawi were sacriﬁced and fasting blood sam-
ples were collected for plasma chemical analysis. Total
amount of cholesterol, LDL-cholesterol, HDL-cholesterol,
serum triglyceride, and blood glucose were measured by
an automatedanalyzer (Cobas-Mira Plus,Hoﬀman-LaRoche
Diagnostics, Germany).
2.7. Radioimmunoassay. Plasma insulin, leptin, and adi-
ponectin levels were determined by radioimmunoassay
(RIA). Rat Insulin-speciﬁc RIA kit, Rat Leptin RIA kit, or
Mouse Adiponectin RIA kit-125T were used. Generally, the
samples were incubated in 12 × 75 mm polypropylene RIA
tubes with rat 125I-insulin, 125I-leptin, or 125I-adiponectin
and a primary antibody against rat insulin, rat leptin, or
mouse adiponectin, respectively, at 4◦C overnight in the
dark. The tubes were then incubated with the precipitating
reagent for 20min at 4◦C and centrifuged at 5350g forEvidence-Based Complementary and Alternative Medicine 3
15min. Radioactivity in the pellet was measured using
a gamma counter (Wallac Wizard 1470, Perkin Elmer,
Waltham, MA). Human insulin, rat leptin, or mouse
adiponectin were used as respective standards.
2.8. Triglyceride Assay in Liver and Skeletal Muscle Tis-
sues. Tissue was homogenized and extracted with a 2:1
chloroform-methanol mixture and washed by addition of
50mM NaCl solution, resulting into two phases. The lower
phase contained the total lipid extract. A ﬁxed volume of this
extract was dried, resuspended inisopropanoland an aliquot
was used fortriglyceride measurement using triglyceride and
free glycerol reagents. Absorbance was measured at ambient
temperature at 540nm using a Wallac Victor 2 plate reader
(Perkin-Elmer, Waltham, MA). Triglyceride content of the
tissue was expressed as mg/g of wet weight of tissue.
2.9. Western Blot for Proteins Involved in Glucose Homeostasis.
Samples of liver and skeletal muscle tissues were ground in
liquid nitrogen and subsequently lysed. For ACC western
blot analysis, 1mL of RIPA lysis buﬀer was used (25mM
Tris-HCl pH 7.4, 25mM NaCl, 0.5mM EDTA, 1% Triton-
X-100, 0.1% SDS), whereas sucrose lysis buﬀer (20mM
Tris-HCl pH 7.4, 255mM sucrose, 1mM EDTA) was used
for Glut4. For all samples, a protease inhibitor cocktail
was added (Roche, Mannheim, Germany) as well as 1mM
phenylmethanesulfonyl ﬂuoride and phosphatase inhibitors
(1mM sodium orthovanadate, 10mM sodium pyrophos-
phate, 10mM sodium ﬂuoride). Cells were allowed to lyse
for 30min on ice and were then centrifuged at 12000 × g
for 10min. Supernatants were then stored at −80◦Cu n t i l
analysis. Protein content was assayed by the bicinchoninic
acid method standardized to bovine serum albumin (Roche,
Laval, QC).
Lysates were diluted to a concentration of 1.25mg/mL
total protein and boiled for 5min in reducing sample buﬀer
(62.5mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 5% β-
mercaptoethanol and 0.01% bromophenol blue). 20μLo f
each sample was separated on 10% polyacrylamide mini-
gels and transferred to nitrocellulose membrane (Millipore,
Bedford, MA). Membranes were blocked for 2h at room
temperature with Tween-20 and 5% skim milk in TBS
(20mM Tris-HCl, pH 7.6 and 137mM NaCl). Membranes
were then incubated overnight at 4◦C in blocking buﬀer
withappropriatephospho-speciﬁcorpan-speciﬁcantibodies
against ACC and Glut4 at 1:1000. Membranes were washed
5 times and incubated 1.5h at room temperature in TBS
plus Tween 20 with anti-rabbit HRP-conjugated secondary
antibodies at 1:100000 to 1:50000. Revelation was per-
formed using the enhanced chemiluminescence method and
luminescence captured to blue-light-sensitive ﬁlm (Amer-
sham Biosciences, Buckinghanshire, England). Lysates from
all experimental conditions were separated and transferred
simultaneously to a single membrane.
2.10. Statistical Analysis. Data are reported as the mean
± SEM of the indicated number of experiments. Results
were analysed by one-way analysis of variance (ANOVA)
using StatView software (SAS Institute Inc, Cary, NC), with
posthoc analysis as appropriate. Statistical signiﬁcance was
set at P ≤ .05.
3.Results
3.1. Body Weight Is Not Signiﬁcantly Aﬀected by NSE. The
results of body weight are presented in Table 1.A tt h eb e g i n -
ning of the trial period (day 0), the diabetic Meriones shawi
weighed between 177g–187g as compared to approximately
158g for non-diabetic controls. At the end of four weeks
of treatment, an increment of weight of about 6 to 10g for
each Meriones shawi group was observed, but no signiﬁcant
diﬀerence was apparent between them, albeit the weight gain
of NSE-treated animals had a tendency to be lower.
3.2. NSE Improves Blood Glucose of Diabetic Meriones
shawi. Daily NSE treatment for four weeks resulted in a
gradual decrease in glycemia that reached values similar
to normal non-diabetic controls animals by the end of
the treatment period (reduction from 8.2 ± 0.5mmol/L
to 6.4 ± 0.3mmol/L, P<. 05, n = 8, Figure 1). By
comparison, metformin reduced blood glucose from 9.2 ±
0.4mmol/L to 5.4 ± 0.4mmol/L (P<. 05, n = 8, Figure 1)
within the ﬁrst week and glycemia remained stable until
the end of the study. In contrast, both diabetic and non-
diabetic control animals displayed stable glycaemia during
the four weeks of treatment; normal animals demonstrated
normal blood sugar levels and control diabetic animals were
hyperglycaemic throughout the study period (Figure 1).
3.3. NSE Reduces Insulin Resistance in the Diabetic Meri-
ones shawi. An oral glucose tolerance test (OGTT) was
performed at the beginning of the study to identify the
Meriones shawi that developed diabetes after three months
of relatively hypercaloric diet. Another OGTT was also
carried out on all selected study animals at the end of the
treatment to determine the eﬀect of NSE- and metformin-
positive control on insulin resistance. Figure 2 presents the
changes in blood sugar observed during the two hours
following administration of the glucose load. As can be
seen, normal (non-diabetic) control animals had a small
response to the glucose load as compared to control diabetic
Meriones, indicating glucose intolerance/insulin resistance
in the latter group. Treatment of diabetic animals for
four weeks with the positive control metformin succeeded
in completely restoring the OGTT response to that of
non-diabetic congeners. In contrast, NSE-treated animals
displayed a signiﬁcant improvement in insulin sensitivity,
but the glyceamic response to the OGTT was intermediate
between normal and diabetic Meriones controls. The AUC
of the glyceamic response to the glucose load over time
conﬁrmed and quantiﬁed the interpretation of Figure 2.
Indeed, all diabetic animals showed similarly elevated AUC
values at the beginning of the experimental protocol as
compared to non-diabetic controls (Table 2). In diabetic
Meriones shawi treated for four weeks with metformin, the
values of the AUC fell signiﬁcantly to reach values seen in4 Evidence-Based Complementary and Alternative Medicine
Table 1: Evolution of body weight over the course of the 4-week treatment.
Time (week) N. sativa (g ± SEM) Metformin (g ± SEM) Diabetic control (g ± SEM) Normal control (g ± SEM)
0 178 ± 17 177 ± 11 187 ± 15 158 ± 14
1 172 ± 16 166 ± 11 178 ± 15 153 ± 12
2 183 ± 19 180 ± 10 186 ± 15 161 ± 13
3 185 ± 18 183 ± 9 192 ± 16 166 ± 13
4 184 ± 16 184 ± 9 197 ± 15 170 ± 12
No statisticallysigniﬁcant diﬀerences were observed between experimental groups at any of the time points (n = 8p e rg r o u p ,N . S . ) .
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Figure 1: Changes of plasma glucose in diabetic Meriones shawi
treated with NSE. Meriones shawi received a daily oral administra-
tionof NSE of 48mg/kgor 300mg/kg metformin(positive control)
whereas normal control group (NC) and diabetic control (DC)
groups received the methyl-cellulose vehicle. Results are expressed
as mean ± SEM (n = 8). Signiﬁcantly diﬀerent from diabetic
control (DC) group at the same time point, ∗P<. 05.
non-diabeticcontrols.Bycomparison,NSEtreatment forthe
same period signiﬁcantly reduced the levelsof AUC to values
slightly greater than those of non-diabetic animals.
3.4. Plasma Lipid Proﬁle: Diﬀerential Modulation by Met-
formin and NSE. In the diabetic Meriones shawi,t r e a t m e n t
for 4 weeks with 48mg/kg/day NSE or 300mg/kg/day
metformin increased total plasma cholesterol concentration
by 49% and 38%, respectively, and the HDL-cholesterol
concentration by 142% and 92%, respectively, as compared
to the diabetic control group (Table 3). These increases
brought levels of total cholesterol and HDL-cholesterol close
to values observed in the normal control group, although
HDL-cholesterol in NSE-treated animals had a tendency
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Figure 2: Eﬀect of NSE on oral glucose tolerance test (OGTT)
in diabetic Meriones shawi. OGTT (glucose 2g/kg) was performed
on fasted animals and blood glucose measured at the onset of
glucose challenge (0min) and at various time points afterwards
(15–120min). Results are expressed as mean ± SEM (n = 8).
Signiﬁcantlydiﬀerent from diabetic control (DC) ∗P<. 05.
to be higher. Plasma LDL-cholesterol concentration was
equivalent in all groups of Meriones shawi (Table 3), whereas
metformin induced a signiﬁcant rise in plasma triglycerides,
as compared to control diabetic animals (Table 3).
3.5. NSE Increases Insulinemia but Does Not Aﬀect Circulating
Leptin or Adiponectin. Untreated diabetic Meriones shawi
exhibited a signiﬁcant increase in plasma insulin as com-
pared to their non-diabetic congeners (P<. 05, n = 8,
Figure 3). Treatment for four weeks with metformin reduced
insulinemia back to levels observed in normal controls.
In contrast, NSE treatment signiﬁcantly increased plasma
insulin levels beyond those observed in the diabetic control
group (P<. 05, n = 8, Figure 3).Evidence-Based Complementary and Alternative Medicine 5
Table 2: Area-under-the-curve (glyceamic (mmol/L)∗time (min)) for OGTT before and after 4-week treatment.
Time (week) Treatment
N. sativa Metformin Diabetic control Normal control
0 1648 ± 107 1685 ± 84 1666 ± 82 956 ± 61§
4 1163 ± 81∗§ 819 ± 54∗§ 1514 ± 83 941 ± 41§
∗Signiﬁcantlydiﬀerent from week 0; P<. 05; §Signiﬁcantly diﬀerent from Diabetic controls; P<. 05.
Table 3: Eﬀect of NSE on blood biochemistry and tissue lipid parameters.
Normal control Diabetic control N. sativa Metformin
Plasma total cholesterol (mmol/L) 0.86 ± 0.09 0.65 ± 0.08 0.97 ± 0.08∗ 0.90 ± 0.10
Plasma LDL-cholesterol (mmol/L) 0.13 ± 0.04 0.10 ± 0.06 0.16 ± 0.05 0.08 ± 0.06
Plasma HDL-cholesterol (mmol/L) 0.48 ± 0.07 0.26 ± 0.05 0.63 ± 0.04∗ 0.50 ± 0.08∗
Plasma triglyceride (mmol/L) 0.55 ± 0.08 0.50 ± 0.04 0.41 ± 0.08 0.72 ± 0.09∗
Plasma leptin (ng/mL) 8.60 ± 2.00 3.50 ± 1.20 3.20 ± 0.50 5.00 ± 1.70
plasma adiponectin (μg/mL) 8.59 ± 1.86 8.50 ± 1.34 5.51 ± 1.32 6.35 ± 1.86
Liver triglyceride (mg/g of tissue) 35.1 ± 18.0 83.3 ± 43.2 28.1 ± 13.5 79.8 ± 31.6
Muscle triglyceride (mg/g of tissue) 5.23 ± 1.10 8.92 ± 3.50 4.23 ± 0.78 10.5 ± 4.39
∗Signiﬁcantlydiﬀerent from Diabetic controls; P<. 05.
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Figure 3: Eﬀect of NSE on plasma insulin levels in Meriones shawi.
The plasma insulin was measured after 4 weeks of treatment in
diabetic control group (DC), normal control group (NC), and
animals receiving 48mg/kg/day N. sativa ethanolic extract (NSE)
or300mg/kg/dayofthereference oralantidiabetic drugmetformin.
Resultsareexpressed asmean±SEM(n = 8).Signiﬁcantlydiﬀerent
from diabetic control animals (DC) ∗P<0.05. Signiﬁcantly
diﬀerent from normal (non-diabetic) control animals (NC) $P<
.05.
The determination of plasma leptin in diﬀerent groups
of diabetic Meriones shawi yielded very similar values irre-
spective of NSE or metformin treatment. However, plasma
leptininnormal Meriones shawi was foundtobesigniﬁcantly
higher than values observed in control diabetic animals
(Table 3). In contrast, the results of plasma adiponectin
showed no signiﬁcant diﬀerences between groups, although
NSE and metformin treated animals had a tendency to have
lower adiponectin values (Table 3).
3.6. NSE Tends to Reduce Liver and Skeletal Muscle Triglyc-
eride Content. As detailed in Table 3,l i v e ra n ds k e l e t a lm u s -
cle triglyceride content appeared to be elevated in control
diabetic versus non-diabetic Meriones shawi and metformin
treatment didnot change this tendency.In contrast, NSEhad
a tendencyto decreasethe triglyceridecontentofbothtissues
(Table 3). Becauseof the large data variability, however, none
of these changes reached statistical signiﬁcance.
3.7. NSE Increases Muscle ACC Phosphorylation and Glut4
Protein Content. In order to begin understanding the mech-
anisms through which the eﬀects of NSE are mediated,
we assessed some key intracellular components involved in
glucose homeostasis. We ﬁrst evaluated the phosphorylation
of ACC, a major component of the AMPK pathway. As
shown in Figure 4, NSE treatment signiﬁcantly increased the
phosphorylation of ACC in liver (panel (a)) and skeletal
muscle (panel (b)) in comparison with control diabetic
Meriones shawi. Secondly, we probed the soleus muscle
tissue of control and NSE-treated diabetic animals for their
total content in Glut4 protein content. As illustrated in
Figure 4(c), NSEsubstantially increased theamount ofGlut4
present in the soleus muscle of diabetic Meriones shawi
animals.
4.Discussion
N. sativa seeds are used in the traditional medicine of
numerous Middle Eastern and North African countries for
their antihyperglycemic activity [26–28]. Most studies to
date have reported results from either normal animals or
models of Type I diabetes [9, 12–15, 17–20], or from cells
in culture [21, 24]. Only a single study presented limited
evidence for an antidiabetic eﬀect of N. sativa in an animal6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀect of NSE on the phosphorylation of ACC in skeletal
muscle and liver tissues and on Glut4 expression in skeletal muscle
tissue. Samples of soleus muscle (a) and (c) and liver (b) tissues
were obtained from diabetic Meriones shawi treated with NSE
or vehicle (DC) and analysed by immunoblotting with antibody
speciﬁc to phospho-ACC (a) and (b) and Glut4 (c). Immunoblots
are representatives of results obtained from four animals of each
group.
model of Type II diabetes [16]. The present study focussed
on antidiabetic and hypolipidemic eﬀects in the Meriones
shawi model of Type II diabetes and aimed to elucidate the
mechanisms of action of NSE in skeletal muscle and liver
tissues (Figure 5).
Meriones shawi are rodents from semi-arid regions of
M o r o c c ot h a tc a ng a i nw e i g h ta n db e c o m ei n s u l i nr e s i s t a n t
and diabetic if kept in captivity (reduced physical activity)
and fed normal laboratory chow (hypercaloric relative to
their natural diet) [16]. This was conﬁrmed in our study by
the greater body weight of the Meriones shawi animals that
also demonstratedinsulin resistance as assessed byan OGTT,
as compared to non-diabetic animals maintaining normal
glucosetolerance.TreatmentwithNSEormetforminforfour
weeks failed to signiﬁcantly aﬀect body weight, although a
tendency for smaller weight gain was seen in NSE-treated
animals as compared to untreated diabetic controls. This
contrasts with the results of Labhal and collaborators who
reported a decrease in body weight among Meriones shawi
treated with an aqueous extract of N. sativa [16]; similar
results having been obtained with the sand rat Psammomys
obesus[8]. Aside fromthe diﬀerencein N. sativa extract type,
the treatment period of these studies lasted three months. It
is therefore possible that our shorter treatment regimen and
use of an ethanol extract may explain the lack of an eﬀect on
body weight in the present studies.
In contrast, our studies conﬁrmed the oral hypoglycemic
action of N. sativa in an animal model of Type II diabetes. As
mentioned, such a decrease in blood glucose was reported in
several studies using animal models of type I [9, 10, 15, 17–
20] and on similar models of Type II diabetes [8, 16]. In
our experimental conditions, NSE decreased blood sugar
starting from the 3rd week of treatment whereas metformin
normalized glycaemia within ﬁrst week. It is known that
thiazolidinediones(TZD)alsodecreasebloodsugarafter3or
4 weeks of treatment [29]. In vitro studies in our laboratory
have conﬁrmed that NSE stimulates PPAR-γ in cultured
adipocytes as do TZD [25]. Part of the action of NSE on
the regulation of blood glucose in vivo may therefore be
similar toTZDs.However,thelackofeﬀectofNSEonplasma
leptin and adiponectin indicates that the action of NSE on
adipose tissuemaynotimplicatethemodulationofthesetwo
adipokines in the Meriones shawi model.
Moreover, the decrease of blood glucose by NSE was
associated with a signiﬁcant reduction in insulin resistance,
as revealed by the pattern of the OGTT response in diabetic
animals and the resulting signiﬁcant decrease in AUC that
clearly indicate an improvement in glucose tolerance. This
improvement in insulin sensitivity is fully consistent with
our previous results showing increases of basal and insulin
stimulatedphospho-Aktinhepatocytesisolatedfromnormal
rats treated with the petroleum ether extract of N. sativa
[22].
NSE treatment also modulated the lipid proﬁle of dia-
beticMeriones shawi,mostnotablybysigniﬁcantlyincreasing
HDL-cholesterol, an eﬀe c tt h a tw eh a v ep r e v i o u s l yo b s e r v e d
in normal rats with a diﬀerent N. sativa extract [22]. We also
observedatendencytowardsa decreaseintriglyceridesinthe
NSE-treated group. Labhal et al. [16]o b s e r v e das i g n i ﬁ c a n t
decrease in blood triglycerides in the same animal model
using an aqueous extract of N. sativa administered for a
period of three months. Once again, diﬀerences in extract
type and treatment period may explain discrepancies with
our results at the level of blood lipid proﬁle.
However, our studies went further by assessing triglyc-
eride content in insulin-sensitive tissues, notably skeletal
muscle and liver. Although the apparent NSE induced
decrease in these parameters failed to reach statistical signif-
icance, such an action could participate in the improvement
of systemic insulin sensitivity observed in our studies.
Indeed, it is known that high levels of intracellular triglyc-
erides can increase some lipid metabolites such as ceramides,
diacylglycerol, and long-chain acyl-coenzyme A [30]. The
latter play a key role in attenuating insulin signaling by
increasing intracellular serine-threonine phosphorylation of
IRS protein, with a resultant reduction in insulin signal
transduction that underlies insulin resistance [30].
More importantly, the NSE-treated Meriones shawi also
showed a large increase in insulinemia after 4 weeks of
treatment that can contribute to the antihyperglycemic
eﬀect of NSE. Such an increase was previously observed
by our group in normal rats [22] and is also observed
in streptozotocin-nicotinamide hamsters [18]. In addition,
treatment of pancreatic β cells in culture with N. sativa was
found to increase insulin secretion as a result of an improved
secretagogue capacity of these cells [21]. On the other hand,
N. sativa increases regeneration ofpancreatic β cells [20]a n d
protects the same from streptozotocin [10]. Our own recentEvidence-Based Complementary and Alternative Medicine 7
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Figure5:NSEactivates AMPKintheliverandmusclestoimproveglucosemetabolism.NSEmediatesitsactionbystimulatingtheadenosine
monophosphate-activated protein kinase (AMPK), an enzyme essential. It also reduces the enzymatic pathway involved in increasing fatty
acid production by the liver (ACC = acteyl-CoA carboxylase); thus,it increases the sensitivity to insulin.The activation ofAMPK can inhibit
the pathway of gluconeogenesis in the liver. In the muscle, NSE activates AMPK towards allowing the increased synthesis and translocation
of Glut4 and consequently increases glucose transport in muscle. NSE also acts on the pancreas by increasing the secretion of insulin.
in vitro studies clearly demonstrate that NSE can enhance
the proliferation of β cells and increase glucose stimulated
insulin secretion [24]. Taken together, these actions can
explain the important increase in insulin levels observed in
diabeticNSE-treatedMeriones shawi (Figure 5).Theyfurther
support the notionthat N. sativa productscanhelp maintain
pancreatic β-cell mass and hence mitigate the progression of
diabetes. Future studies will have to ascertain that this also
occurs in the Merione shawi model.
Our studies also attempted to examine certain key
intracellular components involved in glucose homeostasis.
Western blot analysis showed that NSE treatment in vivo
can signiﬁcantly increase the total amount of Glut4 glucose
transporters in skeletal muscle, which play a major role in
controlling hyperglycemia [31]. Moreover, Glut4 proteins
are known to be subject to transcriptional regulation that
allows for their increased synthesis [32], with a resultant
contributionin reducing hyperglycemia. Further studies will
be necessary to determine the mechanisms underlying the
action of NSE to increase skeletal muscle Glut4, but this
action is likely very relevant to the overall glucose-lowering
activity of the plant (Figure 5).
Finally, we assessed ACC, a key component of the
insulin-independent, metabolic sensing, AMPK pathway
[33]. Indeed, our group recently reported on the stimulation
of ACC and the AMPK pathway by NSE in both skeletal
muscle and hepatocyte cell lines in vitro [25]. In the present
studies, we found thatNSEtreatment in vivo canincrease the
phosphorylation of ACC in liver and skeletal muscle tissues.
The phosphorylation of ACC reduces its activity and results
inadecreaseoflipogenesisintheliverandanincreaseoffatty
acid oxidation in skeletal muscle [34]. These eﬀects on lipid
metabolism can underlie the tendency for NSE to reduce
plasma and tissue triglycerides observed herein. Lastly, it is
known that the activation of the AMPK pathway can lead
to increased synthesis of Glut4 [35] ,a n dt h i si sa l s oi n
accordance with our results (Figure 5).
In conclusion, NSE greatly improves systemic glucose
homeostasis and HDL-cholesterol in diabetic Meriones shawi
by acting through several mechanisms. Most importantly,
N. sativa increases circulating insulin and enhances the
sensitivity of peripheral tissues to the hormone. The latter
eﬀect can be attributed in part to an activation of the
AMPK pathway in skeletal muscle and liver and to an
increased contentofGlut4in skeletalmuscle(Figure 5).Such
pleiotropic actions provide strong evidence in support of
the traditional use of N. sativa seeds for the treatment of
diabetes. They further call for high-quality clinical studies
to determine the optimal conditions for complementary or
alternative treatment in diabetic patients.
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